Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
MD Eric J Lenze, MD Caline Mattar, MD Charles F Zorumski, BA Angela Stevens, Julie Schweiger, MD Ginger E Nicol, J Philip Miller, MPH Lei Yang, MSIS Michael Yingling, MS Michael S Avidan, MBBCh Angela M Reiersen
JAMA, doi:10.1001/jama.2020.22760
IMPORTANCE Coronavirus disease 2019 (COVID-19) may lead to serious illness as a result of an excessive immune response. Fluvoxamine may prevent clinical deterioration by stimulating the σ-1 receptor, which regulates cytokine production. OBJECTIVE To determine whether fluvoxamine, given during mild COVID-19 illness, prevents clinical deterioration and decreases the severity of disease. DESIGN, SETTING, AND PARTICIPANTS Double-blind, randomized, fully remote (contactless) clinical trial of fluvoxamine vs placebo. Participants were community-living, nonhospitalized adults with confirmed severe acute respiratory syndrome coronavirus 2 infection, with COVID-19 symptom onset within 7 days and oxygen saturation of 92% or greater. One hundred fifty-two participants were enrolled from the St Louis metropolitan area (Missouri and Illinois) from April 10, 2020, to August 5, 2020. The final date of follow-up was September 19, 2020. INTERVENTIONS Participants were randomly assigned to receive 100 mg of fluvoxamine (n = 80) or placebo (n = 72) 3 times daily for 15 days.
MAIN OUTCOMES AND MEASURES The primary outcome was clinical deterioration within 15 days of randomization defined by meeting both criteria of (1) shortness of breath or hospitalization for shortness of breath or pneumonia and (2) oxygen saturation less than 92% on room air or need for supplemental oxygen to achieve oxygen saturation of 92% or greater.
RESULTS Of 152 patients who were randomized (mean [SD] age, 46 [13] years; 109 [72%] women), 115 (76%) completed the trial. Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009). The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events.
CONCLUSIONS AND RELEVANCE In this preliminary study of adult outpatients with symptomatic COVID-19, patients treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days. However, the study is limited by a small sample size and short follow-up duration, and determination of clinical efficacy would require larger randomized trials with more definitive outcome measures.
Adverse Events The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events (Table 3 and eResults 1 in Supplement 2). Pneumonia and gastrointestinal symptoms (such as nausea and vomiting) occurred more often in the placebo group compared with those who received fluvoxamine.
Missing Data In terms of missing data, 517 of 3943 follow-up surveys (13%) were not filled out by participants. The mean score for those Body mass index category, No. (%) c Underweight (<18.5) 1 Normal (18.5-24.9) 14 (18) 7 (10) Overweight (25-29. ). For primary prevention, traditional public health approaches include wearing masks, physical distancing, contact tracing, and quarantine. These steps are the current standard of care as the world awaits the results of randomized trials of vaccines and monoclonal antibodies. For the treatment of patients with serious illness in the hospital, corticosteroids have emerged as the standard of care. 1, 2 But what about treatments for patients with COVID-19 who are neither hospitalized nor severely ill? The pilot study by Lenze and colleagues 3 addresses a critically important question during the pandemic of how to prevent individuals who acquire COVID-19 from deteriorating to serious illness. 4 If an effective treatment is found for this key gap in treatment, it will affect the health of millions of people worldwide. This study has important..
References
Cdc Covid-, 19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19), Morbid Mortal Weekly Rep
Chastain, Osae, Henao-Martínez, Racial disproportionality in Covid clinical trials, N Engl J Med
Cobos, Entrena, Nieto, Pharmacology and therapeutic potential of sigma(1) receptor ligands, Curr Neuropharmacol
Gillings, Koch, The application of the principle of intention-to-treat to the analysis of clinical trials, Drug Information J,
doi:10.1177/009286159102500311Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Hallifax, Houston, Saturable uptake of lipophilic amine drugs into isolated hepatocytes, Drug Metab Dispos
Hashimoto, Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication, J Pharmacol Sci
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Ishikawa, Ishiwata, Ishii, High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine, Biol Psychiatry
Ishima, Fujita, Hashimoto, Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells, Eur J Pharmacol
Lescure, Bouadma, Nguyen, Clinical and virological data of the first cases of COVID-19 in Europe, Lancet Infect Dis
Mehta, Mcauley, Brown, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet
Mofsen, Rodebaugh, Nicol, When all else fails, listen to the patient, JMIR Ment Health
Nicol, Piccirillo, Mulsant, Lenze, Action at a distance, J Am Geriatr Soc
Prasad, Prasad, Single virus targeting multiple organs, Front Med
Rosen, Seki, Fernández-Castañeda, Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis, Sci Transl Med
Wiersinga, Rhodes, Cheng, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19), JAMA
